Rainer Strotmann
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.
Journal: Clinical and translational science
Published: September 04, 2025
Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P-Gp: Drug Interaction Studies and Physiologically-Based Pharmacokinetic Analysis.
Journal: Clinical and translational science
Published: March 13, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.
Journal: Clinical and translational science
Published: June 04, 2024
Explainable machine learning prediction of edema adverse events in patients treated with tepotinib.
Journal: Clinical and translational science
Published: April 30, 2024
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.
Journal: Clinical lung cancer
Published: February 28, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 19, 2024
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
Journal: Cancer chemotherapy and pharmacology
Published: November 29, 2021
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Journal: Cancer chemotherapy and pharmacology
Published: November 26, 2021
Adaptive gene regulation in the Striatum of RGS9-deficient mice.
Journal: PloS one
Published: October 18, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026